Israeli-led firm developing AI-guided cardiac sonography raises $24 million to expand in US market

“We are entering this next stage as our FDA-cleared portfolio continues to expand to support broader cardiac imaging workflows,” said Davidi Vortman, CEO and Co-Founder of UltraSight.

“This financing will help us translate that momentum into wider market adoption, deeper strategic collaborations, and greater access to high-quality cardiac ultrasound – expediting care for patients who simply cannot afford to wait,” he added.

Alive HealthTech Growth Fund led the financing, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures. Existing investors Mayo Clinic Ventures, NYU, and Iron Nation also participated.

The Mayo Clinic disclosed in the announcement that it “has a financial interest in the technology, but it will use any revenue it receives to support its not-for-profit mission in patient care, education and research.”

“UltraSight combines clinical evidence with a scalable commercial model in a market constrained by access and workforce shortages,” said Dudi Klein, Alive Co-Founder and Managing Partner.

“We believe the company has developed technology, leadership, and strategic collaborations that position it to support the evolution of cardiac workflows across care settings,” he added.

According to Professor Rafi Beyar, Interventional Cardiologist and General Partner at Alive, the system created by UltraSight “has the potential to transform how imaging supports diagnosis and treatment in structural heart disease.”

The company stated that its Echosystem platform is currently deployed at over ten commercial sites in intensive care settings.

“This financing positions UltraSight to scale that foundation and extend the impact of an AI-guided cardiac workflow platform across cardiovascular care,” added Rick Geoffrion, recently appointed Chairman of the UltraSight Board.